Gadolinium-enhanced Mri
Gadolinium-enhanced Mri - Related Videos
08:36
Functional Neuroimaging Using Ultrasonic Blood-brain Barrier Disruption and Manganese-enhanced MRI
0 Views •
Cited by 4 •
2012
A technique is described for broadly opening the blood-brain barrier in the mouse using microbubbles and ultrasound. Using this technique, manganese can be administered to the mouse brain. Because manganese is an MRI contrast agent that accumulates in depolarized neurons, this approach enables imaging of neuronal activity.
05:15
An Aptamer-based Sensor for Unchelated Gadolinium(III)
0 Views •
2017
The use of polydeoxynucleotide (44-mer aptamer) molecules for sensing unchelated gadolinium(III) ion in an aqueous solution is described. The presence of the ion is detected via an increase in the fluorescence emission of the sensor.
11:38
In vivo Imaging of Optic Nerve Fiber Integrity by Contrast-Enhanced MRI in Mice
0 Views •
Cited by 7 •
2014
This video illustrates a method, using a clinical 3 T scanner, for contrast-enhanced MR imaging of the naïve mouse visual projection and for repetitive and longitudinal in vivo studies of optic nerve degeneration associated with acute optic nerve crush injury and chronic optic nerve degeneration in knock-out mice (p50KO).
04:11
DCE-MRI of Orthotopic Pancreatic Tumor Xenografts: A Method to Assess Microvasculature in a Target Tumor Tissue
0 Views •
2023
This video describes the technique of DCE-MRI for orthotropic pancreatic tumor xenografts in mice. DCE-MRI is a non-invasive method to analyze microvasculature in a target tissue, and useful to assess vascular response in a tumor following a novel therapy. This method will assist investigators to apply DCE-MRI for orthotopic gastrointestinal cancer mouse models.
06:06
Optogenetic Functional MRI
0 Views •
Cited by 15 •
2016
This protocol describes the steps and data analysis required to successfully perform optogenetic functional magnetic resonance imaging (ofMRI). ofMRI is a novel technique that combines high-field fMRI readout with optogenetic stimulation, allowing for cell type-specific mapping of functional neural circuits and their dynamics across the whole living brain.
FAQs
Gadolinium-based contrast agents alter the relaxation behavior of nearby hydrogen protons. Their principal imaging effect in this setting is shortening T1 relaxation time, allowing affected regions to recover longitudinal magnetization more rapidly between radiofrequency measurements. On T1-weighted images, that altered signal can create brighter enhancement, making differences in tissue or abnormal regions easier to recognize than on unenhanced scans.
Not necessarily. Enhancement commonly reflects blood flow, vascularity, or disruption of the blood-brain barrier, and these processes occur in more than one disease context. Gadolinium-enhanced MRI can show findings associated with tumors, but also with inflammation, infection, vascular disease, or organ damage. Interpretation requires linking the enhancement pattern to the broader clinical examination.
In brain imaging, disruption of the blood-brain barrier can allow contrast-related enhancement in regions where barrier integrity has changed. The resulting T1-weighted signal provides an imaging clue about this physiologic or pathologic alteration. Clinicians consider that clue when evaluating neurologic abnormalities, while recognizing that enhancement must be interpreted with the complete MRI and clinical context.
When tissues, blood vessels, or abnormalities are difficult to distinguish on unenhanced images, contrast can increase their visibility by highlighting regions that receive or retain the agent. The resulting signal difference may support characterization rather than simply adding brightness. This is useful when clinicians investigate suspected tumors, inflammation, infection, vascular disease, or organ damage.
During the contrast portion, a gadolinium-based agent is administered intravenously, and MRI images are acquired to show how tissues and abnormalities appear after exposure. T1-weighted images are particularly important because the agent's T1-shortening effect can produce brighter signal. Clinicians can compare this enhanced visibility with the rest of the MRI examination to characterize relevant findings.
Renal function matters because contrast safety is part of the decision to administer a gadolinium-based agent. Clinicians consider the patient's kidney status before proceeding, alongside the expected diagnostic benefit. This assessment is especially relevant when enhanced imaging could improve characterization of a suspected abnormality, because the examination must address both clinical usefulness and patient-specific safety concerns.
By making relevant abnormalities more conspicuous, enhancement can help clinicians characterize disease before selecting or planning treatment. The same examination can also contribute to assessment of disease response, because the visibility and distribution of enhancing findings provide information for clinical comparison over time. Its applications include tumors, inflammation, infection, vascular disease, and organ damage.